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In 2013 the European Atherosclerosis panel [1] highlighted the 
under diagnosis and under treatment of patients with heterozygous 
familial hypercholesterolaemia (heFH) in most, if not all, European 
countries. In the UK, NICE recently updated its clinical guideline 
(CG71) to primary care doctors for screening patients and identifying 
patients with heFH [2]. Are we any closer to knowing the true 
prevalence of heFH?
Using the infamous expression by Donald Rumsfeld there are 
known knowns (those recorded as having heFH) known unknowns 
(those who have had their cholesterol measured, but not labelled as 
heFH) and the unknown unknowns (do we know the population 
prevalence of heFH). The estimated prevalence of heFH within the EU 
ranges from the lower end prediction of 1:500 [1] to an upper end rate 
of 1:137 in a white Danish population cohort from the Copenhagen 
General Population Study [3] using the Dutch Lipid clinic Network 
(DLCN) criteria as definite / probable 
Using the prevalence criteria of 1: 500 the EU panel calculated 
that the Netherlands had diagnosed 71% of the heFH population [1], 
while the UK had diagnosed only 12% giving a diagnosed prevalence 
rate of 1:700 and 1:4,160 respectively. In a study from Medway clinical 
commission group (CCG) to identify undiagnosed patients with heFH, 
in the study population of 262,000, the initial heFH prevalence rate was 
1:750 which increased to 1:375 at the end of the study period [4].
Why is all this so important? Firstly, patients with heterozygous 
familial hypercholesterolaemia have an increased risk of premature 
coronary heart disease and for any given LDL- cholesterol level their 
risk differs from risk charts for patients without heFH, in that their risk 
is from a cumulative high cholesterol from birth. This is why it is so 
important to identify these individuals early (primary patients without 
cardiovascular disease) and reduce their risk through lowering their 
lipid levels. In one series of patients with heFH, the risk of a coronary 
event by age 40, 50, and 65 years was 24%, 51% and 85% respectively 
[5]. In one study of first and second-degree relatives of heFH patients, 
the risk of fatal and nonfatal CHD by age 60 was 52% for male and 32% 
for female relatives [6].
Secondly, we need to know if our strategies are identifying some or 
all of the heFH population. Thirdly the differing screening programme 
strategies required to identify the heFH primary population will have 
cost and resource implications. Is there another way to estimate the 
prevalence in the heFH population without existing CV disease and 
who therefore may not have had their lipids measured? In the UK the 
primary care Quality Outcomes Framework incentivises GPs to ensure 
that all patients with diabetes have their lipids checked. Using UK 
primary care data from The Health Improvement network (THIN), 
the author has calculated the heFH prevalence rate of 1:210 of patients 
with diabetes AND who do not have a current / previous diagnosis of 
cardiovascular disease AND who have an existing recorded diagnosis of 
heFH. A study in the Netherlands [7] of the prevalence of type 2 diabetes 
in heFH patients v unaffected relatives showed that the prevalence of 
heFH in patients with type 2 diabetes was lower at 0.6:1. If we apply this 
reduced rate of heFH in patients with type 2 diabetes to the UK rate of 
heFH in patients with diabetes we would estimate a prevalence rate of 
heFH of 1:125 for the UK general population. This estimate aligns very 
closely with the figure of 1:137 from the Copenhagen study [3]. 
While it is relatively easy in a primary care database to identify 
patients with heFH who have already had their lipids measured by 
utilising an algorithm (DLCN or Simon Broome), identifying the 
remaining group is more difficult and resource intensive 
The NICE guidance [2] advised GPs to screen and counsel all first-
degree relatives of patients with premature heart disease and referring 
the person to an FH specialist service for DNA testing if they meet 
the Simon Broome criteria for possible or definite FH, or they have a 
DLCN score greater than 5. If any are positive then carry out cascade 
testing using DNA testing to identify affected first- and second- and, 
when possible, third-degree biological relatives of people with a genetic 
diagnosis of FH. To find these patients, consent from the index case 
would also be required. NICE indicates that of those genetically 
screened at one centre, 31% have a confirmed diagnosis [8].
Undertaking such a potential large population screening exercise in 
any country will require the resource of specialist personnel to identify, 
track, counsel and test people, in addition to the costs of laboratory 
testing of lipids and of genetic testing. In the UK no additional funding 
has been allocated or ring fenced for this, which will seriously impact 
on its implementation. Other EU countries also do not appear to have 
implemented the EU panel guidelines and its implementation will 
require a regional support infrastructure, in addition to provision of 
local resources. 
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